Management of Comorbidities in Diabetics With Renal Cell Carcinoma: Past Utilization and Current Outcomes
Conclusion:
Reinforcing guidelines compliance for hyperlipidemia management in patients with DM may provide a considerable cancer benefit if diagnosed with RCC. Studies evaluating the need for cholesterol-lowering pharmacotherapy in guidelines-noncompliant DM cases upon RCC diagnosis are currently needed.
Source: Journal of Pharmacy Practice - Category: Drugs & Pharmacology Authors: Rabey, J. L., Yin, J., Kublas, T. M., Mashtare, T., Ceacareanu, A. C. Tags: Research Articles Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cholesterol | Diabetes | Diabetes Mellitus | Drugs & Pharmacology | Endocrinology | Hypertension | Kidney Cancer | Nutrition | Renal Cell Carcinoma | Study